Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants

Shah, Shamita B.; Ohlsson, Arne; Halliday, Henry L.; Shah, V

doi:10.1002/14651858.cd002057

Cited by 22 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[18] When inhaled steroid was used as an alternative strategy to prevent and treat BPD, there was no beneficial effect. [19,20] Infants with BPD have elements of fluid retention and reactive airways; however diuretics, [21,22] and bronchodilators, [23] do not prevent the development of BPD. The use of caffeine has recently emerged as a new strategy.…”

Section: Introductionmentioning

confidence: 99%

Respiratory management of extremely low birth weight infants: survey of neonatal specialists

Parat

Mhanna

2016

World J Pediatr

View full text Add to dashboard Cite

Variability in treatment strategies of ELBW is common among neonatal specialists. However, the majority of the respondents agreed or strongly agreed to use early CPAP for the management of RDS, consider a FiO2 ≥0.4 and a MAP ≥10 cm H2O as criteria for surfactant therapy, and sometimes or almost always used caffeine to prevent BPD. Steroids continue to have a role in the management of BPD in infants who are difficult to extubate.

show abstract

Section: Introductionmentioning

confidence: 99%

Respiratory management of extremely low birth weight infants: survey of neonatal specialists

Parat

Mhanna

2016

World J Pediatr

View full text Add to dashboard Cite

show abstract

“…The trials did not demonstrate significant change on the BPD rate at 28 days or 36 weeks postmenstrual age (PMA) regardless of whether the therapy was given early (<7 days) or late (>7 days). In addition, inhaled steroids have been found to offer no advantage over systemic steroid therapy 24, 25 . Major concerns with inhaled corticosteroids included the type of steroids, dosage, the potential for systemic absorption, and uncertainty regarding drug delivery.…”

Section: Introductionmentioning

confidence: 99%

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ghanta

Leeman

Christou

2013

Seminars in Perinatology

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before 26 completed weeks of gestation. It is characterized by the need for assisted ventilation and/or supplemental oxygen at 36 weeks’ postmenstrual age. Approaches to prevention and treatment of BPD have evolved with improved understanding of its pathogenesis. This review will focus on recent advancements and detail current research in pharmacotherapy for BPD. The evidence for both current and potential future experimental therapies will be reviewed in detail. As our understanding of the complex and multifactorial pathophysiology of BPD changes, research into these current and future approaches must continue to evolve.

show abstract

“…Several clinical trials evaluating dexamethasone as a treatment for CLD did not identify the presence of IH as an outcome measurement [11,12]. Dexamethasone tends to be used in infants with more severe respiratory insufficiency.…”

Section: Discussionmentioning

confidence: 99%